Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (NDAQ:AZN)

LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

Business Wire August 14, 2019

TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer

Business Wire August 9, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

GlobeNewswire August 7, 2019

LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

Business Wire August 7, 2019

BioCardia Signs Exclusive Development Agreement With AstraZeneca

GlobeNewswire July 25, 2019

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer

Business Wire July 22, 2019

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer

Business Wire June 27, 2019

CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

Business Wire June 15, 2019

LOKELMA(TM) Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis

Business Wire June 14, 2019

FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

Business Wire June 10, 2019

IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer

Business Wire June 2, 2019

Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide

Business Wire May 22, 2019

FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma

Business Wire May 20, 2019

AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer

Business Wire May 8, 2019

Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards

Business Wire May 3, 2019

Mid-Afternoon Market Update: Dow Down Over 200 Points; Precipio Shares Spike Higher

Benzinga.com  April 9, 2019

Mid-Day Market Update: Command Center Surges Following Merger Deal With Hire Quest; Hollysys Automation Shares Slide

Benzinga.com  April 9, 2019

Mid-Morning Market Update: Markets Open Lower; PhaseBio Gets Breakthrough Therapy Designation For PB2452

Benzinga.com  April 9, 2019

The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

Benzinga.com  April 9, 2019

AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation

Benzinga.com  April 1, 2019